Enterprise Value
141.3M
Cash
122.5M
Avg Qtr Burn
-15.42M
Short % of Float
19.29%
Insider Ownership
10.58%
Institutional Own.
86.04%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
YUTIQ Details Chronic non-infectious uveitis | Phase 4 Update | |
DEXYCU Details Post-operative inflammation | Approved Quarterly sales | |
EYP-1901 Details Non-proliferative diabetic retinopathy | Phase 2 Data readout | |
EYP-1901 Details Macular degeneration, Wet age-related macular degeneration Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2 Data readout |